
    
      Primary objective is to evaluate the safety and feasibility of the XACT stent and emboshield
      with Angiomax as the procedural anticoagulant.

      Primary safety endpoint is the occurrence of Major Adverse Events, defined as death,
      myocardial infarction (Q or non Q wave), and from target revascularization at one year
    
  